

Horng-Jyh Harn (韓鴻志) MD PhD

**Professor, Department of Pathology
China Medical University
Taichung, Taiwan**

PROFESSIONAL TRAINING :

- 1982-1986** Residency, Pathology Department
Tri-Service General Hospital, Taiwan
- 1986-1987** Chief Resident, Pathology Department
Tri-Service General Hospital, Taiwan
- 1987-1991** Ph.D. Molecular biology, Pathology Department
Duke University, Durham, NC, USA
- 1995-1997** Cellular Pathology and Molecular biology, Clinical fellow
John Radcliffe Hospital, Oxford University, Oxford, UK
Director of Surgical Pathology, Tri-service General hospital, Taipei,
Taiwan
- 1997-2000.....**Residency, Emergency Department,
Tri-Service General Hospital, Taiwan
- 2002, Aug to 2007, Oct –**
Director of Molecular Medicine, Tzu-Chi Buddhist General Hospital,
Hualien, Taiwan
- 2007, Oct to 2011, Apr –**
Chairman, Professor, Pathology department, China Medical University
Hospital, Taichung, Taiwan

Current Research:

Dr. Harn current research interests focus on new drug development and stem cell research for neurological disease to perform translation medicine for pharmaceutical and clinical applications.

Biography:

Horng-Jyh Harn, M.D. Ph.D. current serves at the department of pathology at China Medical University as a professor and surgical pathologist at China Medical hospital, Taichung, Taiwan. Previously, he was a professor in the Department of Pathology at the National Defense Medical Center, Taipei, Taiwan (1997-2002). He receives his surgical pathology training at Tri-Service General Hospital, Taipei, Taiwan. He also owns PhD degree at pathology department of Duke University, Durham, USA (1987-1991). His main research interesting fields are molecular biology, tumor oncology, stem cell research and new drug development against neurological disease.

Select Literatures:

Tsai NM, Lin SZ, Lee CC, Chen SP, Su HC, Chang WL, Harn HJ*. The anti-tumor effects of Angelicae Sinensis on malignancy brain tumor in vitro and in vivo. *Clinical Cancer research*, 2005 May 1;11(9):3475-84.

Chen YL, Lin SZ, Chang JY, Chang WL, Cheng YL, Harn HJ*.

A novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells in vitro and in vivo study" *Biochemical*

Pharmacology 72(2006)308-319

Lin PC, Chen YL, Chiu SC, Yu YL, Chen SP, Chien MH, Chen KY, Chang WL, Lin SZ, Chiou TW, Harn HJ*. Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy

on glioblastoma multiform brain tumor. *Journal of Neurochemistry*. 2008 Aug;106(3):1017-26.

Chen YL, Jian MH, Lin CC, Kang JC, Chen SP, Lin PC, Hung PJ, Chen JR, Chang WL, Lin SZ, Harn HJ*. The induction of orphan nuclear receptor Nur77 expression by n-butylphthalide as pharmaceuticals on hepatocellular carcinoma cell therapy.

Molecular Pharmacology. 2008 Oct;74(4):1046-58. 2008 Jun 24.

Harn HJ*, Lin SZ, Lin PC, Liu CY, Liu PY, Chang LF, Yen SY, Hsieh DK, Liu FC, Tai DF, Chiou TW. Local interstitial delivery of z-butylidene-phthalide by polymer wafers against malignant human gliomas. *Neuro-Oncology* 2011 Jun;13(6):635-48.

Harn HJ*, Lin SZ, Hung SH, Subeq YM, Li YS, Syu WS, Ding DC, Lee RP, Hsieh DK, Lin PC, Chiou TW. Adipose-Derived Stem Cells Can Abrogate Chemical-Induced Liver Fibrosis and Facilitate Recovery of Liver Function. *Cell Transplant*. 2012 Jul 5

Harn HJ*, Huang MH, Huang CT, Lin PC, Yen SY, Chou YW, Ho TJ, Chu HY, Chiou TW, Lin SZ. Rejuvenation of aged pig facial skin by transplanting allogeneic granulocyte colony-stimulating factor-induced peripheral blood stem cells from a young pig. *Cell Transplant*. 2013 Feb 26.

Liu PY, Lin SZ, Sheu JJ, Lin CT, Lin PC, Chou YW, Huang MH, Chiou TW, Harn HJ* Regulation of androgen receptor expression by

Z-isochaihulactone mediated by the JNK signaling pathway and might be related to cytotoxicity in prostate cancer.

Prostate. 2013 Apr;73(5):531-41.

Huang MH, Lin SZ, Lin PC, Chiou TW, Harn YW, Ho LI, Chan TM, Chou CW, Chuang CH, Su HL, Harn HJ*. Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability.

Tumour Biol. 2014 Jan 26.